Curatis Holding Ag · SIX:CURN
Curatis — Merger or Acquisition (January 2024)
16 slides from Curatis's merger presentation, Jan 29, 2024
Slide 1: Curatis – Kinarus Company Presentation & Transaction Summary
CURATIS – KINARUS Company Presentation & Transaction Summary 29 January 2024
Slide 2: Vision: To become a leading European Specialist Medicines Company
Vision: To become a leading European Specialist Medicines Company by focusing on the acquisition, development and commercialization of innovative medicines for the prevention, diagnosis and treatment of rare and specialty care diseases
Slide 3: Background on the transaction
Background on thetransaction ▪ Curatis is a privately held, financially independent Swiss Specialist Medicines Company founded in 2002 ▪ Curatis Distribution Business ▪ 33 Medicines ▪ Revenue generating, profitable and cash flow positive ▪ Curatis Development Business ▪ 1 late-stage Ultra Orphan cli
Slide 4: Investment Case
Investment Case ▪ Curatis generally has balanced, low risk ▪ Experienced board and management team with business model with a mix of distribution track record in development and commercialization Curatis is a and drug development activities of Orphan Drug products Experienced European Board and Spec
Slide 5: Speciality Medicines Distribution Business Strategy
Speciality Medicines Distribution Business Strategy Distribution of third-party products focused on rare diseases and specialty medicines Cash Flow Generating Base Business Examples of Products Distributed ▪ The Base Business of Curatis is a Swiss Specialist Medicines Distribution Business, whereby
Slide 6: Development Pipeline
Development Pipeline Preclinical I IIa IIb Pivotal Phase III MA POC Peritumoral Brain C-PTBE-01 1 pivotal trial Edema in children envisaged Pivotal Phase III with relatively small C-AM-01 patient number, Migraine with Aura 24-36 months including preparation Medication Overuse Headache C-MOH-01 Vario
Slide 7: C-PTBE-01: Peritumoral Brain Edema in Children
A. C-PTBE-01: Peritumoral Brain Edema in Children ▪ Peritumoral brain Edema (PTBE) in children ▪ For certain malignant brain tumors in children no curative therapy is available ▪ Average survival time after diagnosis: 9 months ▪ Main treatment goal: quality of life ▪ Tumor induced edema (PTBE) is a
Slide 8: C-AM-01: Migraine with Aura
B. C-AM-01: Migraine withAura ▪ Migraine Auras are the sensory symptoms (neurologic, gastrointestinal, and autonomic) that can occur before or during a migraine episode ▪ Symptoms can ▪ include flashes of light, blind spots, or tingling in the hands or face ▪ look like a more serious condition, such
Slide 9: C-MOH-01: Medication Overuse Headache
C. C-MOH-01: Medication Overuse Headache ▪ Headache characterized by worsening as result from Medication Overuse ▪ Frequent and prolonged use of medication for the acute treatment ▪ Paradoxical effect: Analgesic medication increase headache frequency/intensity ▪ No approved drug for treatment/preven
Slide 10: Development Roadmap
Development Roadmap Various potentially significant value inflection points Main development 2024E 2025E 2026E 2027E 2028E programs C-PTBE-01 Orphan Drug Designation Pivotal Study Phase III Licensing Deal US NDA FDA NDA EMA Potential Rare Pediatric Disease Voucher Commercialization in US Commerciali
Slide 11: Board of Directors and Executive Management Team
Board of Directors and Executive Management Team Board of Directors (subject to approval at the Company’s EGM) Dr. Marian Borovsky Günter Graubach ▪ Chairman of the Board of Directors ▪ Executive Member of the Board of Directors ▪ Previously Group General Counsel of Actelion ▪ Previously Roche, Sant
Slide 12: Envisaged Transaction Structure
Envisaged Transaction Structure(subjecttoapprovalbytheEGM) 1 Financing Transaction ▪ New Investors to invest CHF4.1m into Curatis AG as Mandatory Exchangeable Loan Note (the “Loan Note”) in the context of the Approx 3,000 Shareholders 10 Shareholders I1 In contemplated transaction SH1 SH2 SH3 SH3000
Slide 13: Transaction Highlights: Curatis & Kinarus
Transaction Highlights: Curatis& Kinarus ▪ Kinarus Therapeutics Holding AG (in Liquidation) is listed on SIX Swiss Exchange (Symbol: KNRS), based in Basel (Canton BS) Involved ▪ Curatis AG (“Curatis”) is privately-held, based in Liestal, BL Entities ▪ Kinarus Holding to continue trading on SIX Swiss
Slide 14: Transaction Highlights: Curatis & Kinarus
Transaction Highlights: Curatis& Kinarus ▪ Curatis and its advisors have worked closely with the bankruptcy administration of Basel-Stadt ▪ Following the outcome of a Schuldenruf, measures have been taken to mitigate risks for Kinarus Holding from any liability claim ▪ Thereafter, the Board of Direc
Slide 15: Important Notice
Important Notice THIS PRESENTATION AND ITS CONTENTS ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY JURISDICTION WHERE SUCH DISTRIBUTION IS UNLAWFUL. This presentation (the
Slide 16: Slide 16
Curatis Holding — Merger or Acquisition (January 2024) on 6ix